Van Putten T, May P R, Marder S R, Wittmann L A
Arch Gen Psychiatry. 1981 Feb;38(2):187-90. doi: 10.1001/archpsyc.1981.01780270073010.
Sixty-three newly admitted schizophrenic patients were given a test dose of thiothixene and their subjective response was recorded by a technician blind to clinical ratings. All patients were then treated wih thiothixene in an active milieu setting. Patients varied widely in their subjective responses. An initial dysphoric response was a powerful predictor of both immediate and eventual drug refusal. Before treatment, dysphoric responders tended to be less symptomatic and did significantly better on the Continuous Performance Test. Dysphoric responders experienced significantly more extrapyramidal symptoms following the test dose. Some dysphoric responders did have a good outcome when treated with very low doses. We recommend that patients with a history of dysphoric response be given a very low dose initially.
63名新入院的精神分裂症患者接受了硫利达嗪的试验剂量,一名对临床评分不知情的技术人员记录了他们的主观反应。然后,所有患者在积极的环境中接受硫利达嗪治疗。患者的主观反应差异很大。最初的烦躁反应是立即和最终拒绝服药的有力预测指标。治疗前,烦躁反应者的症状往往较轻,在连续操作测试中的表现明显更好。烦躁反应者在试验剂量后出现明显更多的锥体外系症状。一些烦躁反应者在使用极低剂量治疗时确实有良好的疗效。我们建议,有烦躁反应史的患者最初给予极低剂量。